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Abstract
Joint models for longitudinal and time-to-event data are commonly used in longitudinal
studies to forecast disease trajectories over time. While there are many advantages to
joint modeling, the standard forms suffer from limitations that arise from a fixed model
specification and computational difficulties when applied to high-dimensional datasets. In
this paper, we propose a deep learning approach to address these limitations, enhancing
existing methods with the inherent flexibility and scalability of deep neural networks while
retaining the benefits of joint modeling. Using longitudinal data from two real-world medical
datasets, we demonstrate improvements in performance and scalability, as well as robustness
in the presence of irregularly sampled data.
1. Introduction
Building a Disease Atlas for clinicians involves the dynamic forecasting of medical conditions
based on clinically relevant variables collected over time, and guiding them in charting a
course of action. This includes the simultaneous prediction of survival probabilities, risks of
developing related diseases, and relevant biomarker trajectories at different stages of disease
progression. While prognosis, i.e. survival prediction, is usually the main area of focus (van
Houwelingen and Putter, 2011; Rizopoulos et al., 2017), a growing area in precision medicine
is the forecasting of personalized disease trajectories, using patterns in temporal correlations
and associations between related diseases to predict their evolution over time. (Jensen et al.,
2014; Kannan et al., 2017). Dynamic prediction methods that account for these interactions
are particularly relevant in multimorbidity management, as patients with one chronic disease
typically develop other long-term conditions over time (Farmer et al., 2016). With the
mounting evidence on the prevalence of multimorbidity in aging populations around the
world (Xu et al., 2017), the ability to jointly forecast multiple clinical variables would be
beneficial in providing clinicians with a fuller picture of a patient’s medical condition.
A substantial portion of machine learning literature investigates predictions with time-
series data, typically focusing on patients in the hospital. In this setting, patients are tracked
for a relatively short period of time, spanning from a few days to weeks, with measurements
collected every few hours. This leads to the collection of numerous measurements, potentially
with a high degree of missingness. Given the length of the monitoring period, in-hospital
predictions are usually narrow in their scope, focusing on detecting the rapid onset of critical
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Figure 1: Illustration of Disease-Atlas Predictions over Time
events, such as ICU admission, and not considering the prediction of comorbidities which
can take years to develop.
With chronic diseases however, such as cystic fibrosis or diabetes, patients are followed
up over the span of years, usually as part of regular physical examinations. This differs
significantly from the in-hospital setting as measurements are collected infrequently, e.g.
once every few years and possibly at irregular intervals, leading to relatively few observations
per patient. The state of the patient also evolves slowly, allowing for the development of
related comorbidities over time. Additional comorbidities in turn affect key biomarkers
which reflect a patient’s clinical state and rate of deterioration, such as lung function scores
(e.g. FEV1) in cystic fibrosis or brain scan measurements in Alzheimer’s disease. As such,
the ability to jointly forecast comorbidity and biomarker trajectories, in addition to survival,
allows for early intervention by clinicians to prevent the development of other related diseases
and forestall further deterioration. This would allow for an improved quality of life for the
patient even if immediate improvements to survival might be small. Hence, the development
of new machine learning methods to combine longitudinal predictions with dynamic survival
(time-to-event) analysis, where events-of-interest can include heart failure, respiratory failure
or the onset of dementia in addition to death, would allow for a more holistic management
of long-term conditions, going above and beyond the short-term survival prediction usually
seen in hospital settings.
Traditionally, joint models for longitudinal and time-to-event data have been commonly
used in clinical studies when there is prior knowledge indicating an association between
longitudinal trajectories and survival. Using individual models for each data trajectory as
building blocks, such as linear mixed models for longitudinal data and the Cox proportional
hazard model for survival, joint models add a common association structure on top of them,
e.g. through shared-random effects or frailty models (Hickey et al., 2016). From a dynamic
prediction perspective, joint models have been shown to lead to a reduced bias in estimation
(Ibrahim et al., 2010) and improved predictive accuracy (Hogan and Laird, 1998). However,
standard joint models face severe computational challenges when applied to large datasets,
which arise when increasing the dimensionality of the random effects component (Hickey
et al., 2016).
To overcome the limitations of joint models, we introduce Disease-Atlas - a scalable deep
learning approach to forecasting disease trajectories over time. Our main contributions are
as follows:
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Deep Learning for Joint Models We provide a novel conception of the joint modeling
framework using deep learning, capturing the relationships between trajectories through
shared representations learned directly from data, and improving scalability as a whole. The
network outputs parameters of predictive distributions for longitudinal and time-to-event
data that take a similar form to the sub-models used in joint modeling. To the best of our
knowledge, this paper is the first to investigate the use of deep learning in joint models for
longitudinal and survival trajectories.
Robustness to Irregular Sampling via Multitask Learning Observations in longitu-
dinal studies are very rarely aligned at every time step, as measurements can be collected at
different sampling frequencies. Hence, training a multioutput neural network would require
the imputation of the target labels as a pre-processing step, so as to artificially align the
dataset prior to calibration. This could lead to poorer predictions if imputation quality is
low and a high degree of missingess is present, as the network is biased to simply learn the
imputation mechanism. To mitigate this issue, we formulate joint model calibration as a
multitask learning problem, grouping variables - which are measured at the same time and
with similar sampling frequencies - together into tasks, and training the network using only
actual observations as target labels.
Incorporating Medical History into Forecasts While deep learning for medicine has
gained popularity in recent times, the majority of methods, such as (Alaa and van der
Schaar, 2017; Ranganath et al., 2016), only use covariates at a single time point in making
predictions. However, a patient’s medical history could also be informative of her future
clinical outcomes, and predictions could be improved by incorporating past information. We
integrate historical information into our network using a Recurrent Neural Network (RNN)
in the base layer, which contains a memory state that updates over time as new observations
come in.
2. Related Work
While the utility of joint models has been demonstrated by its popularity in longitudinal
studies, numerous modeling choices exist, each containing its own advantages and limitations
(see (Hickey et al., 2016) for a full overview). (Rizopoulos et al., 2014), for example, highlight
the sensitivity of predictions to the association structures used, adopting a Bayesian model
averaging approach instead to aggregate the outputs of different models over time. In this
respect, the flexibility of deep learning has the potential to enhance dynamic predictions with
joint models, by directly learning variable relationships from the data itself, and completely
removing the need for explicit model specification. In addition, (Hickey et al., 2016; Barrett
et al., 2015; Waldmann et al., 2017; Futoma et al., 2016) note performance limitations when
applying standard joint models to high-dimensional datasets. These are typically estimated
using Expectation Maximization (EM) or Markov Chain Monte Carlo (MCMC) sampling
methods, which rapidly grow in complexity with the number of covariates and random
effects. As such, most studies and software packages often focus on modeling a single or a
small number of longitudinal measurements, along with a time-to-event of interest. However,
the increase in data availability through electronic health records opens up the possibility
of using information from multiple trajectories to improve predictions. Recent works have
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attempted to address this limitation by exploiting special properties of the longitudinal
sub-models, such as the multivariate skew-normal structure in (Barrett and Su, 2017), and
the combination of variational approximation and dynamic EM-style updates over time
in (Futoma et al., 2016). In light of this, the use of deep learning holds much promise in
enhancing the performance of joint models, given its inherent ability to scale with large
datasets without the need for specific modeling assumptions.
Deep learning has seen increasing use in medical applications, with successes in traditional
survival analysis (Ranganath et al., 2016; Luck et al., 2017) survival analysis with competing
risks (Lee et al., 2018; Alaa and van der Schaar, 2017) and treatment recommendations
(Katzman et al., 2016). In general, these methods focus purely on forecasting survival, do
not consider dynamic prediction over time and only use covariates at a single time point in
making predictions. Deep Kalman Filters (Krishnan et al., 2017) use a network which does
dynamically update its latent states over time but assumes that all outputs follow the same
distribution. This prevents it from being applied to heterogeneous datasets, which limits its
usage for joint modeling.
RNNs with multitask learning have also been used extensively in making predictions
inside the hospital, using frequently sampled measurements as inputs for event detection or
automated diagnosis ((Harutyunyan et al., 2017; Razavian et al., 2016; Li et al., 2015; Lipton
et al., 2016)). In addition to the characteristics of in-hospital data (i.e. sampled at hourly
intervals with a high rate of missing data), these works bear several fundamental differences
to the Disease-Atlas. Firstly, in-hospital predictions focus on separate dynamic classification
tasks which produce single class labels at each time step, such as the most likely event or
diagnosis at the next time step. In contrast, the Disease-Atlas allows for the simultaneous
prediction of multiple variables of interest at each time step, which can be either discrete
(classification) or continuous (regression). As predictions are conditioned on the same latent
structure, we can analyze variables in a consistent fashion and use trajectory forecasts to
understand changes in survival probabilities. For example, poorer survival odds could be a
result of increased risk of multiple infections. Secondly, the RNNs in existing works typically
produce single point forecasts, which do not account for the uncertainty of the model. We
address this limitation using the Monte-Carlo Dropout procedure of (Gal and Ghahramani,
2016) (see Section 4.3), producing predictions with uncertainty estimates at each time step.
3. Problem Definition
For a given longitudinal study, let there be N patients with observations made at time
t, for 0 ≤ t ≤ Tcens where Tcens denotes an administrative censoring time 1. For the
ith patient at time t, observations are made for a K-dimensional vector of longitudinal
variables Vi,t = [Y
(1)
i,t , . . . , Y
(C)
i,t , B
(1)
i,t , . . . , B
(D)
i,t ], where Y
(c)
i,t and B
(d)
i,t are continuous and
discrete longitudinal measurements respectively, a L-dimensional vector of external covariates
Xi,t = [X
(1)
i,t , . . . X
(L)
i,t ], and a M -dimensional vector of event occurrences δi,t = [δ
(1)
i,t , . . . , δ
(M)
i,t ]
, where δ
(m)
i,t ∈ {0, 1} is an indicator variable denoting the presence or absence of the mth event.
T
(m)
i,t is defined to be the first time the event is observed after t, which allows us to model
both repeated events and events that lead to censoring (e.g. death). The final observation
1. Administrative censoring refers to the right-censoring that occurs when a study observation period ends.
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for patient i occurs at Ti,max = min(Tcens, T
(a1)
i,0 , . . . , T
(amax)
i,0 ), where {ai, . . . , amax} is the set
of indices for events that censor observations. Furthermore, we introduce a filtration Fi,t to
capture the full history of longitudinal variables, external covariates and event occurrences
of patient i until time t.
3.1 Joint Modeling
From (Hickey et al., 2016), numerous sub-models for longitudinal measurements exist,
each with their own pros and cons. General forms for continuous and binary longitudinal
measurements are typically expressed as:
Y
(c)
i,u |Fi,t ∼ N
(
m(c)
(
u,Fi,t; bi,W˜
)
, σ(c) 2u
)
(1)
B
(d)
i,u |Fi,t ∼ Bernoulli
(
Φ(d)
(
u,Fi,t; bi,W˜
))
(2)
Where m(c)(.) is a function for the predictive mean of the c-th longitudinal variable, and
σ
(c) 2
t its variance. Φ
(d)(.) is a function for the probability of the binary observation, such as
the commonly used logit or probit functions, and W˜ is the vector of static coefficients used
by the sub-models.
In both models, bi is a vector of association parameters used across trajectories, and
define the association structure of the joint model. While the majority of models use
subject-specific random effects, this can also refer to time-dependent latent variables as seen
in (Ibrahim et al., 2004) or shared spline coefficients in (Barrett and Su, 2017).
Event times can be expressed using the general form below:
T
(m)
i,t |Fi,t ∼ S
(
Λ(m)
(
t,Fi,t; bi,W˜
))
(3)
Where S is an appropriate survival distribution (e.g. Exponential, Weibull, etc), and
Λ(m)(.) is a generic cumulative hazard function. In most joint model applications, this
typically takes the form of the Cox proportional hazards model.
The standard linear mixed effects models can be expressed as:
Y
(c)
i,t = X
>
i,t θ
(c)
fix + R
>
i,t θ
(c)
rand + 
(c)
i,t
= m(c)(t) + 
(c)
t
(4)
h
(m)
i,t = h0(t) exp
(
B>i γ
(m) + β(m)m(c)(t)
)
(5)
Where Xi,t and Ri,t are time-dependent design vectors for fixed effects θ
(c)
fix and random
effects θ
(c)
rand, 
(c)
i,t ∼ N
(
0, σ
(c) 2
t
)
is a random noise term, and h
(m)
i,t is the hazard rate of the
survival process, with patient fixed covariates Bi, and static coefficients γ
(m) and β(m).
In this model, we define the association parameters of the joint model to be those common
to both longitudinal and survival processes, i.e bi = [θ
(c)
fix, θ
(c)
rand], and static coefficients
which are unique to the separate processes, i.e. W˜ = [γ(m), β(m)].
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3.2 Dynamic Prediction
Dynamic prediction in joint models can be defined as the estimation of both the expected
values of longitudinal variables and survival probabilities over a specific time window τ in
the future:
Vˆ
(k)
i (τ |t) = E
[
V
(k)
i,t+τ |Fi,t; bi,W˜
]
(6)
S
(m)
i (τ |t) = P
(
T
(m)
i,0 ≥ t+ τ |T (m)i,0 ≥ t,Fi,t; bi,W˜
)
(7)
Where V
(k)
i,t is the k
th longitudinal variable at time t that can be either continuous or binary.
A conceptual illustration of dynamic prediction can be found in Figure 1. For continuous
longitudinal variables, such as biomarker predictions, the goal is to forecast its expected
value given all the information until the current time step (i.e. Fi,t). In the case of binary
observations, such as the presence of a comorbidity, the expectation in Equation 6 is the
probability (or risk) of developing a comorbidity at time t+ τ . The survival curves shown
give us the probability of not experiencing an event over various horizons τ given Fi,t. While
the uncertainty estimates are model dependent, these are usually expressed via confidence
intervals in frequentist methods, or using the posterior distributions for bi,t and W˜ in
Bayesian models.
4. Network Design
4.1 Architecture
Disease-Atlas captures the associations within the joint modeling framework, by learning
shared representations between trajectories at different stages of the network, while retaining
the same sub-model distributions captured by joint models. The network, as shown in Figure
2, is conceptually divided into 3 sections: 1) A shared temporal layer to learn the temporal
and cross correlations between variables, 2) task-specific layers to learn shared representations
between related trajectories, and 3) an output layer which computes parameters for predictive
sub-model distributions for use in likelihood loss computations during training and generating
predictive distributions at run-time.
The equations for each layer are listed in detail below. For notational convenience, we
drop the subscript i for variables in this section, noting that the network is only applied to
trajectories from one patient at time.
Shared Temporal Layer We start with an RNN at the base of the network, which
incorporates historical information (i.e. Ft) into forecasts by updating its memory state over
time. For the tests in Section 5, the usage of both the Simple Recurrent Network (SRN)
and LSTM in this layer was compared.
[ht,mt] = RNN([Xt,Vt],mt−1) (8)
Where ht is the output of the RNN and mt its memory state. To generate uncertainty
estimates for forecasts and retain consistency with joint models, we adopt the MC dropout
approach described in (Gal and Ghahramani, 2016). Dropout masks are applied to the
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Figure 2: Disease-Atlas Network Architecture
inputs, memory states and outputs of the RNN, and are also fixed across time steps. For
memory updates, the RNN uses the Exponential Linear Unit (ELU) activation function.
Task-specific Layers For the task-specific layers, variables are grouped according to the
sub-model types in Section 3.1, with layer zc,t for continuous-valued longitudinal variables,
zb,t for binary longitudinal variables and ze,t for events. Dropout masks are also applied
to the outputs of each layer here. At the inputs to the continuous and binary task layers,
a prediction horizon τ is also concatenated with the outputs from the RNN. This allows
the parameters of the predictive distributions at t+ τ to be computed in the final layer, i.e.
h˜t = [ht, τ ].
zc,t = ELU(Wch˜t + ac) (9a)
zb,t = ELU(Wbh˜t + ab) (9b)
ze,t = ELU(Weht + ae) (9c)
Output Layer The final layer computes the parameter vectors of the predictive distribu-
tion, which are used to compute log likelihoods during training and dynamic predictions at
run-time.
µt+τ = Wµzc,t + aµ (10a)
σt+τ = Softplus(Wσzc,t + aσ)) (10b)
pt+τ = Sigmoid(Wpzb,t + ap)) (10c)
λt = Softplus(Wλze,t + aλ)) (10d)
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Softplus activation functions are applied to σt+τ and pt+τ to ensure that we obtain valid
(i.e. ≥ 0) standard deviations and binary probabilities. For simplicity, the exponential
distribution is selected to model survival times, and predictive distributions can be expressed
in a similar manner to that of Section 3.1:
Y
(c)
t+τ ∼ N
(
µ
(c)
t+τ , σ
(c)2
t+τ
)
(11a)
B
(d)
t+τ ∼ Bernoulli
(
p
(d)
t+τ
)
(11b)
T
(m)
t ∼ Exponential
(
λ
(m)
t
)
(11c)
4.2 Multitask Learning
From the above, the negative log-likelihood of the data given the network is:
L(W) =
∑
i,t,w,kc,kb,m
−
[
log fc
(
Y
(c)
i,t+τ |µ(c)t+τ , σ(c)2t+τ ,W
)
+ log fb
(
B
(d)
i,t+τ |p(d)t+τ ,W
)
+ log fT
(
T
(m)
i,t |λ(m)t ,W
)]
(12)
Where fc(.), fb(.) are likelihood functions based on Equations 11 and W collectively represents
the weights and biases of the entire network. For survival times, fT (.) is given as:
fT
(
T
(m)
t |λ(m)t ,W
)
=
(
λ
(m)
t
)δi,T
exp
(
−λ(m)t T (m)t
)
(13)
Which corresponds to event-free survival until time T before encountering the event (Dun-
teman and Ho, 2006). While the negative log-likelihood can be directly optimized across
tasks, the use of multitask learning can yield the following benefits:
Better Survival Representations As shown in (Li et al., 2015), multitask learning
problems which have one main task of interest can weight the individual loss contributions
of each subtask to favor representations for the main problem. For our current architecture,
where we group similar tasks into task-specific layers, our loss function corresponds to:
L(W) =− αc
i,t,w,c∑
log fc
(
Y
(c)
t+τ |W
)
︸ ︷︷ ︸
Continuous Longitudinal Loss lc
−αb
i,t,w,d∑
log fb
(
B
(d)
t+τ |W
)
︸ ︷︷ ︸
Binary Longitudinal Loss lb
− αT
i,t,m∑
log fT
(
T
(m)
t |W
)
︸ ︷︷ ︸
Time-to-event Loss lT
(14)
Given that survival predictions are the primary focus of many longitudinal studies, we set αc =
αb = 1 and include αT as an additional hyperparameter to be optimized. To train the network,
patient trajectories are subdivided into Q sets of Ωq(i, ρ, τ) = {Xi,0:ρ,Yi,ρ+τ ,Tmax,i, δi},
where ρ is the length of the covariate history to use in training trajectories up to a maximum
of ρmax. Our procedure follows that of (Collobert and Weston, 2008), as detailed in Algorithm
1.
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Algorithm 1 Training Disease-Atlas
Input: Data Ω = {Ω1, . . . ,ΩQ}, max iterations J
Output: Calibrated network weights W
for count= 1 to J do
Get minibatch M∼ γ random samples from Ω
Sample task loss function l ∼ {lc, lb, lT }
Update W← Adam(l,M), using feed-forward passes with dropout applied
end for
Handling Irregularly Sampled Data We address issues with irregular sampling by
grouping variables that are measured together into the same task, and training the network
with multitask learning. For instance, height, weight and BMI measurements are usually
taken at the same time during follow-up, and can be grouped together in the same task.
Given the completeness of the datasets we consider, we assume that task groupings match
those defined by the task-specific layer of the network, and multitask learning is performed
using Equation 14 and Algorithm 1.
We note, however, that in the extreme case where none of the trajectories are aligned,
we can define each variable as a separate task with its own loss function l∗. Algorithm 1
then samples loss functions for one variable at a time, and the network is trained using only
actual observations as target labels. This could reduce errors in cases where multiple sample
rates exist and simple imputation is used, which might result in the multioutput networks
replicating the imputation process instead of making true predictions.
4.3 Forecasting Disease Trajectories
Dynamic prediction involves 2 key elements - 1) calculating the expected longitudinal values
and survival curves as described in Section 3.2, and 2) computing uncertainty estimates. To
obtain these measures, we apply the Monte-Carlo dropout approach of (Gal and Ghahramani,
2016) by approximating the posterior over network weights as:
p(V
(k)
t+τ |Ft) ≈
1
J
J∑
j=1
p(V
(k)
t+τ |Ft,Wˆj) (15)
Where we draw J samples Wˆj using feed-forward passes through the network with the same
dropout mask applied across time-steps. The samples obtained can then be used to compute
expectations and uncertainty intervals for forecasts.
5. Tests on Medical Data
5.1 Overview of Datasets
The UK Cystic Fibrosis (CF) registry contains data obtained for a cohort of 10980 CF
patients during annual follow ups between 2008-2015, with a total of 87 variables associated
with each patient across all years. In our investigations below, we consider a joint model
for 2 continuous lung function scores (FEV1 and Predicted FEV1), 20 comorbidity and
infection risks (treated as binary longitudinal observations) as well as death as the event
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of interest, simultaneously forecasting them all at each time step. We refer the reader to
Appendix A for a full breakdown of the dataset.
5.2 Benchmarks and Training Procedure
We compared the Disease-Atlas (DA) against simpler neural networks i.e. LSTM and Multi-
layer Perceptrons (MLP), and traditional dynamic prediction methods, i.e. landmarking
(L) (van Houwelingen and Putter, 2011) and joint models (JM). The data was partitioned
into 3 sets: a training set with 60% of the patients, a validation set with 20% and a testing
set with the final 20%. Hyper-parameter optimization was performed using 20 iterations
of random search on the validation data, and the test set was reserved for out-of-sample
testing. Full details on the training procedure can be found in Appendix A. Models were
compared using several metrics: Mean-Squared Error (MSE) for predictions of continuous
longitudinal variables, and the area under the Receiver Operating Characteristic (AUROC)
and Precision-Recall Curve (AUPRC) for binary variables and the event of interest, i.e.
death. Predictions were made via the MC dropout procedure described in Section 4.3, with
expectations computed using 300 samples per time step.
Disease-Atlas Through subsequent tests, we demonstrate the performance contributions
of the different innovations of Disease-Atlas, namely the usage of multitask learning in the
presence of irregular sampling (Section 5.3), and the inclusion of the RNN in the base layer
for temporal information (Section 5.4). For the temporal layer, we evaluate the use of both
a LSTM (DA-LSTM) or a single ELU layer (DA-NN).
Standard Neural Networks Both the LSTM and MLP were taken to be benchmarks,
structured to produce the same output distribution parameters as the Disease-Atlas, and
optimized according to the multioutput loss function in Equation 12. This makes the
benchmarks equivalent to the DA-LSTM and DA-NN structures without task-specific layers
and input τ , and restricts them to making one-step-ahead longitudinal predictions only.
Landmarking For consistency with other studies of Cystic Fibrosis (MacKenzie et al.,
2014), we use age as the time variable, and fit separate Cox regression models for patients in
different age groups (< 25, 25− 50, 50− 75 and > 75 years old). As data is left-truncated
with respect to age, we use the entry-exit implementation of the Cox proportional hazards
model implemented in (Therneau, 2015). To avoid issues with collinearity, we start with
a preliminary feature selection step first - performing multi-step Cox regression on the
validation dataset, and only retaining features with coefficient p-values < 0.1.
Joint Models With the computational limitations of standard joint models, direct ap-
plication to our dataset - containing over 6,500 patients in the training set with 87 annual
covariate measurements - proved to be infeasible. As such, we used the two-step estimation
procedure of (Wu, 2009), fitting the individual linear mixed effects (LME) longitudinal
sub-models first, and using the mean estimates in the Cox regression model. For continuous
variables, the linear mixed effects models used random intercepts and slopes, this is in line
with the FEV1 models in (van Horck et al., 2017), (Van Diemen et al., 2011) and (Stern
et al., 2007). For binary variables, we use the logit regression version of the LME model, as
implemented in the lme4 R package (Bates et al., 2015).
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5.3 Evaluating Multitask Learning with Irregularly Sampled Data
To evaluate the effectiveness of multitask learning, we simulate irregular sampling by randomly
removing all data points across each task (defined in Section 4.2) with a probability γ at
every time step. For multivariate prediction, continuous-valued inputs were imputed using
the mean value of the training set, while binary variables and indicators of death were
set to 0. The networks were trained according to Section 4.2, and then evaluated on the
complete test set based on 1) MSE for continuous variables, and 2) AUROC for binary/event
predictions.
Figure 3 shows the outperformance of multitask learning, which has a lower MSE for
FEV1 and higher AUROCs for comorbidity and mortality predictions as γ increases. The
improvements are most pronounced for MSE, as FEV1 has values at every time step, as
opposed to binary observations and occurrences of death which are relatively more infrequent
in the dataset. This demonstrates the robustness of the model to irregular sampling, and
provides a way for joint models to be used on datasets even under such conditions.
(a) FEV1 MSE (b) Comorbidity AUROC (c) Mortality AUROC
Figure 3: Performance Comparison Between Multitask and Multioutput Networks
5.4 Performance vs Benchmarks
As survival analysis is the usually main task of interest, we perform a comprehensive
evaluation across all benchmarks, computing a probability of the event of interest, i.e. death,
at a given time step using 1− S(m)i (τ |t) from Equation 7. Performance was compared on
the basis of AUROC and AUPRC of mortality predictions at various horizons τ . To account
for the stochastic nature of the MC dropout sampling procedure, performance evaluation
was repeated 3 times for each neural network, with the averages and standard deviations of
the metrics in reported in Table 1.
The first thing to note is the vast improvements of neural networks over traditional
dynamic prediction models, with the DA-LSTM showing average AUPRC improvements of
75% and 78% across all time steps when compared to landmarking and standard joint models.
Among the neural network benchmarks, the strongest gains for the DA-LSTM can be seen
over shorter prediction horizons (1-2 years), improving the DA-NN by 17% and the LSTM
by 21% in one-step-ahead AUPRC. This highlights the benefits of both the use of temporal
information and the addition of task-specific layers for short-term survival predictions. While
the gains in AUROC are indeed smaller, this can be attributed to the large class imbalance
present within the dataset, due to the rare occurrence of death in the dataset (seen in 451
of 10275 patients) and the censoring effect it has on a patients trajectory. As shown in
11
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Table 1: Results of Mortality Predictions for Cystic Fibrosis (Mean ± S.D. Across 3 Runs)
τ DA-LSTM DA-NN LSTM MLP L JM
AUROC 1 0.944(± 0.0004) 0.943(± 0.0003) 0.943(± 0.0007) 0.941(± 0.0003) 0.824 0.870
2 0.924(± 0.0008) 0.923(± 0.0005) 0.923(± 0.0005) 0.919(± 0.0003) 0.812 0.870
3 0.910(± 0.0003) 0.905(± 0.0002) 0.908(± 0.0002) 0.907(± 0.0002) 0.825 0.851
4 0.905(± 0.0003) 0.902(± 0.0008) 0.904(± 0.0003) 0.904(± 0.0006) 0.776 0.828
5 0.895(± 0.0003) 0.892(± 0.0005) 0.894(± 0.0005) 0.888(± 0.0007) 0.765 0.806
AUPRC 1 0.278 (± 0.0037) 0.238 (± 0.0040) 0.230 (± 0.0020) 0.219 (± 0.0036) 0.161 0.119
2 0.193 (± 0.0014) 0.169 (± 0.0033) 0.165 (± 0.0017) 0.186 (± 0.0036) 0.082 0.092
3 0.103 (± 0.0005) 0.092 (± 0.0007) 0.099 (± 0.0028) 0.105 (± 0.0001) 0.085 0.089
4 0.109 (± 0.0007) 0.101 (± 0.0014) 0.095 (± 0.0010) 0.102 (± 0.0006) 0.062 0.068
5 0.101 (± 0.0007) 0.091 (± 0.0008) 0.093 (± 0.0017) 0.100 (± 0.0017) 0.058 0.059
(Saito and Rehmsmeier, 2015), ROC metrics can lead to deceptive good performance, as the
definition of the false positive rate (false positive / total number of negatives) permits the
occurrence of a large number of false positives in imbalanced datasets, and recommend the
use of PRC metrics. In addition, we note that the Disease-Atlas architectures also allow
for the forecasting of longitudinal variables over arbitrary horizons, which standard neural
network architectures are unable to accommodate by default.
Table 2: Results of Longitudinal Predictions for Cystic Fibrosis (Single Run)
MSE AUROC [Mean ± SD] AUPRC [Mean ±SD]
τ FEV1 Pred. FEV1 Comorbidities Infections Comorbidities Infections
DA-LSTM 1 0.182 121.3 0.957 (± 0.025) 0.888 (± 0.056) 0.680 (±0.261) 0.416 (±0.247)
2 0.191 139.4 0.926 (±0.047) 0.850 (± 0.044) 0.648 (± 0.244) 0.337 (± 0.261)
3 0.275 191.3 0.882 (±0.048) 0.798 (± 0.057) 0.555 (± 0.213) 0.337 (± 0.261)
4 0.374 254.4 0.817 (±0.085) 0.723 (± 0.068) 0.459 (± 0.184) 0.309 (± 0.252)
5 0.461 308.1 0.790 (±0.067) 0.669 (± 0.126) 0.388 (± 0.169) 0.269 (± 0.247)
JM 1 0.553 368.6 0.699 (± 0.148) 0.673 (± 0.069) 0.176 (± 0.088) 0.161 (± 0.176)
2 0.593 411.1 0.694 (± 0.139) 0.651 ( ± 0.060) 0.180 ( ± 0.089) 0.157 ( ± 0.181)
3 0.641 451.8 0.685 (± 0.140) 0.631 ( ± 0.072) 0.185 ( ± 0.090) 0.160 ( ± 0.186)
4 0.695 490.1 0.681 (± 0.132) 0.607 ( ± 0.077) 0.187 ( ± 0.091) 0.159 ( ± 0.188)
5 0.750 519.7 0.673 (± 0.130) 0.580 ( ± 0.082) 0.188 ( ± 0.093) 0.155 ( ± 0.186)
We proceed to evaluate the longitudinal forecasting ability of the Disease-Atlas in Table
2, focusing on comparisons between the DA-LSTM and standard joint models. To provide a
concise summary of longitudinal prediction results, we use a single set of 300 MC dropout
samples to compute performance metrics. The average AUROC/AUPRC for comorbidities
and infections are reported separately, along with standard deviations across each group.
Similarly, results for FEV1 and Predicted FEV1 are reported for a single evaluation, and
a full breakdown of results for each individual binary longitudinal variable is detailed in
Appendix A. We can see that the DA-LSTM improves performance across all longitudinal
prediction categories, reducing MSEs by 56% on average across all continuous predictions,
and improving AUPRCs in comorbidities and infections on average by 199% and 112%
respectively. This vast improvement underscores the ability of deep neural networks to learn
complex interactions directly from the data, and demonstrates the benefits of using a deep
learning approach to joint modeling.
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6. Illustrative Use Case for Disease-Atlas: Personalized Screening
While numerous use cases for the Disease-Atlas exist, one possible example is its use in
personalized screening, i.e. prescribing testing regimes and follow-up schedules that are
tailored to the unique characteristics of a patient. (Ahuja et al., 2017) derive an optimal
policy that balances the costs of screening, along with the risks of delaying the screening
process. Their paper, however, has two important limitations: 1) it requires the evolution of
the disease to be known, and 2) it requires an analytical expression for the cost of delay,
which is often difficult to determine in practice. Disease-Atlas does not suffer from these
limitations.
We illustrate how the Disease Atlas can be used for identifying screening profiles for
Cystic Fibrosis patients. We use as an exemplar an actual patient from our test set who
started to be seen in 2008 and is screened for Diabetes, a very important comorbidity
affecting the treatment of patients.
Figure 4 shows how the Disease Atlas can be used to design personalized screening
policies. Using the Disease Atlas as applied from 2008-2010, we can record the “smoothed”
estimate at each time step, i.e. Bˆ
(d)
i (0|t) as per Equation 6 and plotted in orange. To
determine a patient’s future risk, we extrapolate in the usual way over various horizons
τ , providing both the expected value and an uncertainty interval using the 5th and 95th
percentiles of the MC dropout samples. From Figure 6, we see that the patient had a steady
18% increase in risk from 2008 to 2010, and will expect a further increase of 13% over the
next 5 years. Informed by the Disease Atlas, the clinician may decide to prescribe additional
tests for Diabetes, or increase the frequency of follow-up in the short-term to better monitor
risks.
Figure 4: Using Disease-Atlas for Personalized Screening
13
Bryan Lim and Mihaela van der Schaar
References
Kartik Ahuja, William Zame, and Mihaela van der Schaar. Dpscreen: Dynamic personalized
screening. In I. Guyon, U. V. Luxburg, S. Bengio, H. Wallach, R. Fergus, S. Vishwanathan,
and R. Garnett, editors, Advances in Neural Information Processing Systems, NIPS 2017,
pages 1321–1332. 2017.
A. M. Alaa and M. van der Schaar. Deep multi-task gaussian processes for survival analysis
with competing risks. In Advances in Neural Information Processing Systems, NIPS 2017.
2017.
J Barrett and L. Su. Dynamic predictions using flexible joint models of longitudinal and
timetoevent data. Statistics in Medicine., 36(9):1447–1460, April 2017.
Jessica Barrett, Peter Diggle, Robin Henderson, and David Taylor-Robinson. Joint modelling
of repeated measurements and time-to-event outcomes: flexible model specification and
exact likelihood inference. Journal of the Royal Statistical Society: Series B (Statistical
Methodology), 77(1):131–148, 2015.
Douglas Bates, Martin Ma¨chler, Ben Bolker, and Steve Walker. Fitting linear mixed-effects
models using lme4. Journal of Statistical Software, 67(1):1–48, 2015. doi: 10.18637/jss.
v067.i01.
Ronan Collobert and Jason Weston. A unified architecture for natural language processing:
Deep neural networks with multitask learning. In Proceedings of the 25th International
Conference on Machine Learning, ICML 2008, pages 160–167, 2008.
George H. Dunteman and Moon-Ho R. Ho. An Introduction to Generalized Linear Models.
SAGE Publications, Inc., Thousand Oaks, CA, USA, 2006.
Caroline Farmer, Elisabetta Fenu, Norma O’Flynn, and Bruce Guthrie. Clinical assessment
and management of multimorbidity: summary of nice guidance. BMJ, 354, 2016.
Joseph Futoma, Mark Sendak, C. Blake Cameron, and Katherine Heller. Scalable joint
modeling of longitudinal and point process data for disease trajectory prediction and
improving management of chronic kidney disease. In Proceedings of the Thirty-Second
Conference on Uncertainty in Artificial Intelligence, UAI’16, pages 222–231, 2016.
Yarin Gal and Zoubin Ghahramani. A theoretically grounded application of dropout in
recurrent neural networks. In Advances in Neural Information Processing Systems, NIPS
2016, 2016.
Hrayr Harutyunyan, Hrant Khachatrian, David C. Kale, and Aram Galstyan. Multitask
learning and benchmarking with clinical time series data. CoRR, abs/1703.07771, 2017.
URL https://arxiv.org/abs/1703.07771.
Graeme L. Hickey, Pete Philipson, Andrea Jorgensen, and Ruwanthi Kolamunnage-Dona.
Joint modelling of time-to-event and multivariate longitudinal outcomes: recent develop-
ments and issues. BMC Medical Research Methodology, 16(1):117, Sep 2016.
14
Disease-Atlas: Navigating Disease Trajectories using Deep Learning
Joseph W Hogan and Nan M Laird. Increasing efficiency from censored survival data by
using random effects to model longitudinal covariates. Statistical Methods in Medical
Research, 7(1):28–48, 1998.
Joseph G. Ibrahim, Ming Hui Chen, and Debajyoti Sinha. Bayesian methods for joint
modeling of longitudinal and survival data with applications to cancer vaccine trials.
Statistica Sinica, 14(3):863–883, 7 2004.
Joseph G. Ibrahim, Haitao Chu, and Liddy M. Chen. Basic concepts and methods for joint
models of longitudinal and survival data. Journal of Clinical Oncology, 28(16):27962801,
2010.
Anders Boeck Jensen, Pope L. Moseley, Tudor I. Oprea1, Sabrina Gade Ellese, Robert
Eriksson, Henriette Schmock, Peter Bjdstrup Jensen, Lars Juh, Jensen, and Sren Brunak.
Temporal disease trajectories condensed from population-wide registry data covering 6.2
million patients. Nature Communications., 5(4022), 2014.
Venkateshan Kannan, Narsis A. Kiani, Fredrik Piehl, and Jesper Tegner. A minimal unified
model of disease trajectories captures hallmarks of multiple sclerosis. Mathematical
Biosciences, 289:1 – 8, 2017.
Jared Katzman, Uri Shaham, Jonathan Bates, Alexander Cloninger, Tingting Jiang, and
Yuval Kluger. Deepsurv: Personalized treatment recommender system using a cox
proportional hazards deep neural network. In Proceedings of the 33rd International
Conference on International Conference on Machine Learning - Volume 48, ICML 2016,
2016.
Rahul G. Krishnan, Uri Shalit, and David Sontag. Deep kalman filters. CoRR,
abs/1511.05121, 2017. URL https://arxiv.org/abs/1511.05121.
C. Lee, W. R. Zame, J. Yoon, and M. van der Schaar. Deephit: A deep learning approach
to survival analysis with competing risks. In AAAI, 2018.
F Li, L Tran, K-H Thung, S Ji, D Shen, and J. Li. A robust deep model for improved
classification of ad/mci patients. IEEE journal of biomedical and health informatics., 19
(5):1610–1616, 2015.
Zachary C. Lipton, David C. Kale, Charles Elkan, and Randall Wetzel. Learning to
diagnose with lstm recurrent neural networks. In International Conference on Learning
Representations (ICLR), 2016.
Margaux Luck, Tristan Sylvain, He´lo¨ıse Cardinal, Andrea Lodi, and Yoshua Bengio. Deep
learning for patient-specific kidney graft survival analysis. CoRR, abs/1705.10245, 2017.
URL http://arxiv.org/abs/1705.10245.
Todd MacKenzie, Alex H. Gifford, Kathryn A. Sabadosa, Hebe B. Quinton, Emily A. Knapp,
Christopher H. Goss, and Bruce C. Marshall. Longevity of patients with cystic fibrosis
in 2000 to 2010 and beyond: Survival analysis of the cystic fibrosis foundation patient
registry. I Annals of internal medicine, 161(4):233–241, 2014.
15
Bryan Lim and Mihaela van der Schaar
Rajesh Ranganath, Adler Perotte, Nomie Elhadad, and David Blei. Deep survival analysis.
In Proceedings of the 1st Machine Learning for Healthcare Conference, volume 56 of
Proceedings of Machine Learning Research, pages 101–114, 18–19 Aug 2016.
Narges Razavian, Jake Marcus, and David Sontag. Multi-task prediction of disease onsets
from longitudinal laboratory tests. In Proceedings of the 1st Machine Learning for
Healthcare Conference (MLHC), volume 56 of Proceedings of Machine Learning Research,
pages 73–100, Children’s Hospital LA, Los Angeles, CA, USA, 18–19 Aug 2016.
Dimitris Rizopoulos, Laura A. Hatfield, Bradley P. Carlin, and Johanna J. M. Takkenberg.
Combining dynamic predictions from joint models for longitudinal and time-to-event data
using bayesian model averaging. Journal of the American Statistical Association, 109
(508):1385–1397, 2014.
Dimitris Rizopoulos, Geert Molenberghs, and Emmanuel M.E.H. Lesaffre. Dynamic pre-
dictions with time-dependent covariates in survival analysis using joint modeling and
landmarking. Biometrical Journal, 59(6):1521–4036, 2017.
Takaya Saito and Marc Rehmsmeier. The precision-recall plot is more informative than the
roc plot when evaluating binary classifiers on imbalanced datasets. PLoS One, 10(23),
2015.
D. A. Stern, W. J. Morgan, A. L. Wright, S. Guerra, and F. D. Martinez. Poor airway
function in early infancy and lung function by age 22 years: a non-selective longitudinal
cohort study. Lancet, 370, 2007.
Terry M Therneau. A Package for Survival Analysis in S, 2015. URL https://CRAN.
R-project.org/package=survival. version 2.38.
C Van Diemen, D Postma, M Siedlinski, A Blokstra, H Smit, and H. Boezen. Genetic
variation in timp1 but not mmps predict excess fev1 decline in two general population-based
cohorts. Respiratory Research., 12(1), 2011.
Marieke van Horck, Bjorn Winkens, Geertjan Wesseling, Dillys van Vliet, Kim van de Kant,
Sanne Vaassen, Karin de Winter-de Groot, Ilja de Vreede, Quirijn Jbsis, and Edward
Dompeling. Early detection of pulmonary exacerbations in children with cystic fibrosis by
electronic home monitoring of symptoms and lung function. Scientific Reports, 7(1), 2017.
Hans van Houwelingen and Hein Putter. Dynamic Prediction in Clinical Survival Analysis.
CRC Press, Inc., Boca Raton, FL, USA, 2011.
Elisabeth Waldmann, David Taylor-Robinson, Nadja Klein, Thomas Kneib, Tania Pressler,
Matthias Schmid, and Andreas Mayr. Boosting joint models for longitudinal and time-to-
event data. Biometrical Journal, 59(6):1104–112, 2017.
Lang Wu. Mixed Effects Models for Complex Data. Chapman & Hall/CRC, Hoboken, NJ ,
USA, 2009.
Xiaolin Xu, Gita D. Mishra, and Mark Jones. Evidence on multimorbidity from definition
to intervention: An overview of systematic reviews. Ageing Research Reviews, 37:53 – 68,
2017.
16
Disease-Atlas: Navigating Disease Trajectories using Deep Learning
Appendix for Disease-Atlas
A. Tests on Cystic Fibrosis Dataset
A.1 Details on Dataset
The UK Cystic Fibrosis (CF) registry contains data obtained for a cohort of 10980 CF
patients during annual follow ups between 2008-2015, with a total of 87 variables that were
associated with each patient across all years. This includes demographic information (e.g.
age, height, weight, BMI), genetic information, treatments received, metrics for lung function
(FEV1 and Predicted FEV1), comorbidities observed, and any bacterial infections developed.
In our investigations, we consider a joint model for the 2 continuous lung function scores
(FEV1 and Predicted FEV1), 20 binary longitudinal variables of comorbidity and infection,
along with death as the event of interest.
A full description of the jointly-modeled longitudinal and time-to-event datasets can be
found in Table 3.
A.2 Hyperparameter Optimization
Hyperparameter optimization was conducted using 20 iterations of random search, with
the search space documented in Table 4. Please note that the RNN state size was defined
relative to the number of input features (L). The task specific layers were also size in
relation to the RNN state size, and defined to be (state size + task output size) /2. This
was done to ensure that we had a principled way of sizing the task-specific layer relative to
state size and outputs, without having to add on too many additional hyper-parameters
(i.e. one per task-specific layer). In addition, αT was defined in relation to the number of
longitudinal variables (K). All neural networks were trained to convergence, as determined
by the survival log-likelihoods evaluated on the validation data, or up to a maximum of 50
epochs.
The final parameters obtained for each network can be found in Table 5.
A.3 Additional Results
To supplement the results in the test section of the main report, a detailed breakdown
of the prediction results for binary longitudinal variables can be found in Table 6 and 7
for DA-LSTM and JM respectively. For the DA-LSTM, due to the randomness present
in the MC dropout procedure, the performance evaluation was repeated 3 times with the
means and standard deviations reported in the tables. The results also demonstrate the
outperformance of the deep neural network over standard benchmarks in both AUROC and
AUPRC terms.
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Table 3: Description of Longitudinal and Time-to-event Data for CF
Type % Patients Mean S.D. Min Max
Event Death Binary (Event) 4.70% 0.008 0.087 0.000 1.000
Biomarkers FEV1 Continuous 100.00% 2.176 0.914 0.090 6.250
Predicted FEV1 Continuous 100.00% 72.109 22.404 8.950 197
Comorbidities Liver Disease Binary 20.80% 0.128 0.334 0.000 1.000
Asthma Binary 22.96% 0.146 0.353 0.000 1.000
Arthropathy Binary 9.50% 0.050 0.218 0.000 1.000
Bone fracture Binary 1.94% 0.007 0.081 0.000 1.000
Raised Liver Enzymes Binary 23.91% 0.114 0.318 0.000 1.000
Osteopenia Binary 20.37% 0.114 0.318 0.000 1.000
Osteoporosis Binary 9.58% 0.051 0.219 0.000 1.000
Hypertension Binary 3.30% 0.020 0.139 0.000 1.000
Diabetes Binary 24.56% 0.167 0.373 0.000 1.000
Bacterial Burkholderia Cepacia Binary 5.59% 0.034 0.181 0.000 1.000
Infections Pseudomonas Aeruginosa Binary 65.18% 0.407 0.491 0.000 1.000
Haemophilus Influenza Binary 30.55% 0.091 0.288 0.000 1.000
Aspergillus Binary 29.29% 0.110 0.313 0.000 1.000
NTM Binary 6.38% 0.019 0.136 0.000 1.000
Ecoli Binary 5.32% 0.012 0.111 0.000 1.000
Klebsiella Pneumoniae Binary 4.93% 0.010 0.101 0.000 1.000
Gram-Negative Binary 3.78% 0.008 0.089 0.000 1.000
Xanthomonas Binary 13.18% 0.043 0.202 0.000 1.000
Staphylococcus Aureus Binary 52.59% 0.244 0.429 0.000 1.000
ALCA Binary 5.06% 0.020 0.138 0.000 1.000
Table 4: Hyper-parameter Selection Range for Random Search
Hyper-parameter Selection Range
Max Number of Epochs 50
RNN State Size 1L, 2L, 3L, 4L, 5L
αT K, 2K, 3K, 4K, 5K
Max Gradient Norm 0.5, 1.0, 1.5, 2.0
Learning Rate 1e-3, 5e-3, 1e-4
Minibatch Size 64, 128, 256
Dropout Rate 0.2, 0.3, 0.4, 0.5
Table 5: Hyper-parameters Selected for CF Tests
State Size Minibatch Size Learning Rate Max Gradient Norm Dropout Rate αT
DA-LSTM 1L 256 1.00E-04 0.5 0.3 3K
DA-NN 5L 256 1.00E-04 2.0 0.3 4K
Standard LSTM 1L 32 1.00E-03 1.5 0.4 4K
Standard NN 1.5L 64 1.00E-03 1 0.45 1K
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Table 6: AUROC for Comorbidity and Infection Predictions for CF Dataset (Mean ± S.D.
Across 3 Runs)
DA-LSTM 1 2 3 4 5
Comorbidities
Liver Disease 0.975 (± 0.0001) 0.948 (± 0.0001) 0.897 (± 0.0003) 0.826 (± 0.0005) 0.767 (± 0.0001)
Asthma 0.979 (± 0.0001) 0.946 (± 0.0002) 0.906 (± 0.0005) 0.843 (± 0.0004) 0.784 (± 0.0003)
Arthropathy 0.975 (± 0.0004) 0.950 (± 0.0002) 0.911 (± 0.0004) 0.888 (± 0.0007) 0.833 (± 0.0004)
Bone fracture 0.891 (± 0.0024) 0.791 (± 0.0015) 0.789 (± 0.0014) 0.610 (± 0.0029) 0.721 (± 0.0013)
Raised Liver Enzymes 0.937 (± 0.0006) 0.909 (± 0.0002) 0.798 (± 0.0004) 0.741 (± 0.0006) 0.685 (± 0.0002)
Osteopenia 0.961 (± 0.0005) 0.942 (± 0.0003) 0.897 (± 0.0006) 0.873 (± 0.0005) 0.850 (± 0.0004)
Osteoporosis 0.956 (± 0.0006) 0.943 (± 0.0008) 0.912 (± 0.0006) 0.877 (± 0.0008) 0.854 (± 0.0003)
Hypertension 0.977 (± 0.0004) 0.955 (± 0.0006) 0.936 (± 0.0009) 0.879 (± 0.0006) 0.869 (± 0.0009)
Diabetes 0.963 (± 0.0002) 0.942 (± 0.0002) 0.918 (± 0.0001) 0.873 (± 0.0003) 0.844 (± 0.0004)
Infections
Burkholderia Cepacia 0.960 (± 0.0011) 0.929 (± 0.0009) 0.922 (± 0.0008) 0.876 (± 0.0004) 0.846 (± 0.0011)
Pseudomonas Aeruginosa 0.898 (± 0.0004) 0.878 (± 0.0002) 0.850 (± 0.0002) 0.818 (± 0.0003) 0.796 (± 0.0005)
Haemophilus Influenza 0.848 (± 0.0007) 0.835 (± 0.0002) 0.798 (± 0.0002) 0.737 (± 0.0007) 0.738 (± 0.0012)
Aspergillus 0.873 (± 0.0007) 0.798 (± 0.0004) 0.789 (± 0.0007) 0.673 (± 0.0010) 0.665 (± 0.0006)
NTM 0.897 (± 0.0008) 0.802 (± 0.0013) 0.824 (± 0.0014) 0.675 (± 0.0008) 0.633 (± 0.0002)
Ecoli 0.929 (± 0.0018) 0.894 (± 0.0013) 0.733 (± 0.0044) 0.677 (± 0.0043) 0.340 (± 0.0066)
Klebsiella Pneumoniae 0.950 (± 0.0012) 0.904 (± 0.0007) 0.815 (± 0.0044) 0.630 (± 0.0005) 0.725 (± 0.0046)
Gram-Negative 0.745 (± 0.0052) 0.793 (± 0.0045) 0.690 (± 0.0007) 0.698 (± 0.0020) 0.587 (± 0.0027)
Xanthomonas 0.894 (± 0.0009) 0.831 (± 0.0005) 0.770 (± 0.0013) 0.716 (± 0.0007) 0.654 (± 0.0006)
Staphylococcus Aureus 0.908 (± 0.0002) 0.856 (± 0.0004) 0.784 (± 0.0005) 0.699 (± 0.0003) 0.649 (± 0.0005)
ALCA 0.863 (± 0.0008) 0.831 (± 0.0010) 0.800 (± 0.0008) 0.758 (± 0.0010) 0.725 (± 0.0015)
JM 1 2 3 4 5
Comorbidities
Liver Disease 0.634 0.622 0.619 0.607 0.602
Asthma 0.701 0.671 0.649 0.622 0.597
Arthropathy 0.761 0.755 0.755 0.757 0.749
Bone Fracture 0.344 0.379 0.378 0.413 0.411
Raised Liver Enzymes 0.622 0.608 0.589 0.584 0.594
Osteopenia 0.774 0.767 0.761 0.758 0.746
Osteoporosis 0.801 0.794 0.781 0.772 0.76
Hypertension 0.894 0.891 0.893 0.893 0.889
Diabetes 0.76 0.754 0.739 0.723 0.709
Infections
Burkholderia Cepacia 0.636 0.638 0.63 0.622 0.613
Pseudomonas Aeruginosa 0.744 0.735 0.727 0.713 0.692
Haemophilus Influenza 0.698 0.712 0.722 0.715 0.685
Aspergillus 0.716 0.689 0.662 0.622 0.603
NTM 0.709 0.686 0.678 0.633 0.586
Ecoli 0.729 0.604 0.507 0.444 0.389
Klebsiella Pneumoniae 0.777 0.73 0.706 0.67 0.624
Gram-Negative 0.533 0.55 0.53 0.518 0.489
Xanthomonas 0.628 0.613 0.604 0.611 0.603
Staphylococcus Aureus 0.607 0.589 0.577 0.561 0.542
ALCA 0.624 0.613 0.598 0.572 0.552
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Table 7: AUPRC for Comorbidity and Infection Predictions for CF Dataset (Mean ± S.D.
Across 3 Runs)
DA-LSTM 1 2 3 4 5
Comorbidities
Liver Disease 0.862 (± 0.0006) 0.825 (± 0.0007) 0.709 (± 0.0022) 0.616 (± 0.0009) 0.513 (± 0.0012)
Asthma 0.904 (± 0.0006) 0.845 (± 0.0015) 0.773 (± 0.0016) 0.642 (± 0.0024) 0.544 (± 0.0019)
Arthropathy 0.799 (± 0.0036) 0.760 (± 0.0027) 0.621 (± 0.0011) 0.500 (± 0.0038) 0.347 (± 0.0026)
Bone fracture 0.064 (± 0.0020) 0.043 (± 0.0012) 0.052 (± 0.0011) 0.032 (± 0.0011) 0.031 (± 0.0018)
Raised Liver Enzymes 0.784 (± 0.0015) 0.726 (± 0.0019) 0.536 (± 0.0016) 0.409 (± 0.0024) 0.338 (± 0.0011)
Osteopenia 0.758 (± 0.0018) 0.742 (± 0.0013) 0.648 (± 0.0024) 0.577 (± 0.0009) 0.526 (± 0.0017)
Osteoporosis 0.658 (± 0.0044) 0.644 (± 0.0028) 0.507 (± 0.0017) 0.406 (± 0.0013) 0.322 (± 0.0011)
Hypertension 0.308 (± 0.0069) 0.340 (± 0.0072) 0.309 (± 0.0074) 0.277 (± 0.0031) 0.227 (± 0.0010)
Diabetes 0.850 (± 0.0006) 0.798 (± 0.0019) 0.774 (± 0.0013) 0.663 (± 0.0020) 0.640 (± 0.0034)
Infections
Burkholderia Cepacia 0.692 (± 0.0029) 0.672 (± 0.0026) 0.639 (± 0.0047) 0.576 (± 0.0058) 0.471 (± 0.0052)
Pseudomonas Aeruginosa 0.840 (± 0.0002) 0.828 (± 0.0010) 0.815 (± 0.0010) 0.800 (± 0.0007) 0.794 (± 0.0017)
Haemophilus Influenza 0.369 (± 0.0006) 0.332 (± 0.0005) 0.265 (± 0.0007) 0.243 (± 0.0009) 0.278 (± 0.0007)
Aspergillus 0.380 (± 0.0038) 0.315 (± 0.0008) 0.337 (± 0.0019) 0.270 (± 0.0011) 0.293 (± 0.0012)
NTM 0.237 (± 0.0008) 0.073 (± 0.0006) 0.181 (± 0.0017) 0.133 (± 0.0024) 0.138 (± 0.0008)
Ecoli 0.506 (± 0.0040) 0.242 (± 0.0030) 0.089 (± 0.0021) 0.036 (± 0.0005) 0.008 (± 0.0009)
Klebsiella Pneumoniae 0.299 (± 0.0039) 0.146 (± 0.0044) 0.060 (± 0.0041) 0.010 (± 0.0000) 0.015 (± 0.0004)
Gram-Negative 0.028 (± 0.0007) 0.038 (± 0.0013) 0.022 (± 0.0004) 0.027 (± 0.0003) 0.022 (± 0.0004)
Xanthomonas 0.298 (± 0.0068) 0.202 (± 0.0037) 0.218 (± 0.0020) 0.180 (± 0.0022) 0.128 (± 0.0019)
Staphylococcus Aureus 0.771 (± 0.0010) 0.706 (± 0.0018) 0.612 (± 0.0014) 0.537 (± 0.0002) 0.497 (± 0.0006)
ALCA 0.153 (± 0.0011) 0.148 (± 0.0024) 0.155 (± 0.0040) 0.144 (± 0.0019) 0.175 (± 0.0025)
JM 1 2 3 4 5
Comorbidities
Liver Disease 0.181 0.186 0.197 0.2 0.207
Asthma 0.272 0.261 0.258 0.245 0.24
Arthropathy 0.134 0.142 0.148 0.155 0.154
Bone Fracture 0.006 0.007 0.007 0.009 0.01
Raised Liver Enzymes 0.163 0.16 0.156 0.157 0.172
Osteopenia 0.245 0.255 0.266 0.278 0.28
Osteoporosis 0.144 0.149 0.151 0.146 0.134
Hypertension 0.123 0.13 0.141 0.142 0.142
Diabetes 0.319 0.334 0.342 0.348 0.356
Infections
Burkholderia Cepacia 0.054 0.058 0.056 0.056 0.062
Pseudomonas Aeruginosa 0.636 0.641 0.65 0.655 0.649
Haemophilus Influenza 0.181 0.204 0.233 0.231 0.202
Aspergillus 0.22 0.22 0.218 0.212 0.216
NTM 0.076 0.068 0.072 0.062 0.041
Ecoli 0.098 0.037 0.025 0.011 0.005
Klebsiella Pneumoniae 0.051 0.037 0.026 0.025 0.027
Gram-Negative 0.009 0.01 0.012 0.012 0.015
Xanthomonas 0.079 0.079 0.087 0.092 0.098
Staphylococcus Aureus 0.336 0.337 0.344 0.347 0.345
ALCA 0.037 0.04 0.037 0.04 0.047
20
